Here is a link to an extensive list of doctors that should prescribe what one needs. Some of the therapies suggested will need a prescription.

https://covid19criticalcare.com/ivermectin-in-covid-19/covid-19-care-providers/In

-I-RECOVER POST VACCINE TREATMENT

Link to the pdf

https://covid19criticalcare.com/wp-content/uploads/2022/06/An-Approach-to-Vac-Injured-06-09-2022.pdf

-DEFINITION OF POST-VACCINE SYNDROME Although no official definition exists for ‘post-COVID-vaccine syndrome, a temporal correlation between receiving a COVID-19 vaccine and beginning or worsening of a patient’s clinical manifestations is sufficient to diagnose as a COVID-19 vaccine-induced injury, when the symptoms are unexplained by other concurrent causes. Since Phase 3 and Phase 4 clinical trials are still ongoing, the full safety and toxicity profile for COVID-19 vaccines cannot be fully determined. From a bioethical perspective, cases of any new-onset or worsened signs, symptoms or abnormalities following any dose of COVID-19 vaccine must be considered as an injury caused by the vaccine, until proven otherwise.

-EPIDEMIOLOGY

The Centers for Disease Control (CDC), National Institutes for Health (NIH),Food and Drug Administration (FDA) and World Health Organization(WHO) do not recognize post-vaccine injuries and there is no specific ICD classification code for this disease. Thus, the accurate prevalence of post-vaccine syndrome is unknown.[1]

However, as of May 27, 2022, 825,453 adverse events have been reported in the United States alone following COVID-19 vaccination. This includes 163,283 doctor’s office visits, 100,259 urgent care visits, 63,368 hospitalizations, 13,150 deaths, and 12,746 life-threatening events, according to OPEN VAERS, which tracks data recorded in the U.S. Vaccine Adverse Event Reporting System(VAERS).

VAERS data is limited by underreporting, by a factor of at least 30-fold.[2] Furthermore, published trials data suggest that at least 1 to 1.5 percent of vaccinated patients develop serious adverse events following vaccination.[2,3] Since 572 million doses of a COVID-19 vaccine have been administered in the U.S.—and 11 billion worldwide—it is likely there are millions of vaccine-injured patients worldwide, and at least 2 million cases in the U.S.

As the medical community does not recognize this serious humanitarian disaster, these patients have unfortunately been shunned and denied access to the medical care they need and deserve. Furthermore, there is limited clinical, molecular, and pathological data on these patients to inform an approach to treating the condition. Consequently, our approach to the management of vaccine-injured patients is based on the presumed pathogenetic mechanism, as well as the clinical observations of physicians and patients themselves.

-PATHOGENSIS

The spike protein, notably the S1 segment, is likely the major pathogenetic factor leading to post-vaccine syndrome. [4,5] The S1 protein is profoundly toxic. Multiple intersecting and overlapping pathophysiologic processes likely contribute to the vast spectrum of vaccine injuries: [1,6]

A prospective study on 64,900 medical employees, in which reactions to their first mRNA vaccination were carefully monitored, found that 2.1% of subjects reported acute allergic reactions.[11]

The acute myocarditis/sudden cardiac death syndrome that occurs post vaccination(within hours to 48 hours), noted particularly in young athletes, may be caused by a “stress cardiomyopathy” due to excessive catecholamines produced by the adrenal medulla in response to spike protein-induced metabolic aberrations.[12]

The inflammatory response is mediated by spike protein-induced mononuclear cell activation in almost every organ in the body but most notably involving the brain, heart and endocrine organs.

The lipid nanoparticles (LNP) themselves are highly proinflammatory Neuro-COVID, the neurological manifestations related to the spike protein, are related to the complex interplay of neuroinflammation,[18] production of amyloid and prion protein,[19-23] autoantibodies, microvascular thrombosis, and mitochondrial dysfunction. [24]

As the medical community does not recognize this serious humanitarian disaster, these patients have unfortunately been shunned and denied access to the medical care they need and deserve. Furthermore, there is limited clinical, molecular, and pathological data on these patients to inform an approach to treating the condition.

The spike protein is highly thrombogenic, directly activating the clotting cascade; in addition, the clotting pathway is initiated via inflammatory mediators produced by mononuclear cells and platelets. [5] Activation of the clotting cascade leads to both large clots (causing strokes and pulmonary emboli) as well as micro clots (causing microinfarcts in many organs, but most notably the brain)

And finally, due to altered immune function, the activation of dormant viruses and bacterial pathogens may occur, resulting in reactivated Herpes Simplex, Herpes Zoster, Epstein Barr Virus (EBV) and cytomegalovirus (CMV)infection, as well as reactivation of Lyme disease and mycoplasma. [45-47]

The common factor underlying the pathogenic mechanism in the vaccine-injured patient is “immune dysregulation.”

It appears that about 80 percent of vaccine-injured patients are female. Women are known to be at a much higher risk of autoimmune diseases (especially SLE) and this likely explains this finding.

-TREATMENT APPROACH

Our treatment approach is, therefore, based on the postulated pathogenetic mechanism, clinical observation, and patient anecdotes.

The core problem in post-vaccine syndrome is chronic “immune dysregulation.” The primary treatment goal is to help the body to restore and normalize the immune system—in other words to let the body heal itself.

Early treatment is essential; it is likely that the response to treatment will be attenuated when treatment is delayed.

It is likely that COVID-19 will exacerbate the symptoms of vaccine injury.

Hyperbaric oxygen therapy (HBOT)should be considered in cases of severe neurological injury and in patients showing a rapid downhill course

-BASELINE TESTING

We recommend a number of simple, basic screening tests that should be repeated, as clinically indicated, every 4 to 6 months

CBC with differential and platelet count

Standard blood chemistries, including liver function tests

D-Dimer—as a marker of clotting activation

CRP—as a marker of ongoing inflammation (A comprehensive extensive

cytokine/chemokine panel is unnecessary and very costly, and the results will not change the treatment approach.

Early morning cortisol—some patients develop autoimmune adrenal failure)

TSH—to exclude thyroid disease

HbA1C—Vaccine-injured patients are at an increased risk of developing diabetes

Troponin and pro-BNP to exclude cardiac disease.

CMV, EBV, Herpes simplex, HHV6and mycoplasma serology/PCR

Vitamin D level(25OH Vitamin D)

-FIRST LINE THERAPIES

•Intermittent daily fasting or periodic daily fasts; Fasting has a profound effect on promoting immune system homeostasis, partly by stimulating autophagy and clearing misfolded and foreign proteins, promoting mitophagy and improving mitochondrial health, as well as increasing stem cell production.[50-56] Intermittent fasting likely has an important role in promoting the breakdown and elimination of the spike protein.

Fasting is contraindicated in patients younger than 18 (impairs growth) and during pregnancy and breastfeeding. Patients with diabetes, as well as those with serious underlying medical conditions, should consult their primary care physician prior to undertaking fasting, as changes in their medications maybe required and these patients require close monitoring.

For timed fasting, begin slowly: start with an 11-hour eating window 5 days a week and reduce monthly to an 8-hour eating window 7 days a week. For caloric fasting, eat normally for 5 days and fast for 2 days, restricting caloric intake to 500-1000 kcal per day.

“A little starvation can really do more for the average sick man than can the best medicines and the best doctors.” —Mark Twain (1835-1910)

• Do not underestimate fasting as a viable therapy. The research I've seen so far has shown remarkable effects on the body. It could be extremely effective and is why they placed it above Ivermectin. I would go so far as to say it may be a necessary process for optimal health.*

•Ivermectin;0.2-0.3 mg/kg, daily for up to 4-6 weeks.

Ivermectin has potent anti-inflammatory properties. [57-59] It also binds to the spike protein, aiding in the elimination by the host. It is likely that ivermectin and intermittent fasting act synergistically to rid the body of the spike protein.

•Low dose naltrexone(LDN); LDN has been demonstrated to have anti-inflammatory, analgesic and neuromodulating properties.[63,64] Begin with 1 mg/day and increase to 4.5 mg/day, as required. May take 2 to 3 months to see full effect. Prescription needed.

•Melatonin;2-6mg Melatonin has anti-inflammatory and antioxidant properties and is a powerful regulator of mitochondrial function.

•Aspirin;81mg/day

•Vitamin C; 1000 mg orally three to four times a day.

Vitamin C has important anti-inflammatory, antioxidant, and immune-enhancing properties, including increased synthesis of type I interferons. Avoid in patients with a history of kidney stones. Oral Vitamin C helps promote growth of protective bacterial populations in the microbiome.

•Vitamin D and Vitamin K2; The dose of Vitamin D should be adjusted according to the baseline Vitamin D level. However, a dose of 4000-5000 units/day of Vitamin D, together with Vitamin K2 100 mcg/day is a reasonable starting dose.

•Quercetin;250-500 mg/day

Flavonoids have broad spectrum anti-inflammatory properties, inhibit mast cells,[75-79] and have been demonstrated to reduce neuroinflammation.

•Nigella Sativa; 200-500 mg twice daily.

It should be noted that thymoquinone (the active ingredient of Nigella Sativa) decreases the absorption of cyclosporine and phenytoin. Patients taking these drugs should, therefore, avoid taking Nigella Sativa.

•Probiotics/prebiotics

Patients with post-vaccine syndrome classically have a severe dysbiosis with loss of Bifidobacterium.[88-90] Kefir is a highly recommended nutritional supplement high in probiotics. [91] Suggested probiotics include Megasporebiotic (Microbiome labs), TrueBifidoPro (US Enzymes) and yourgutplus+.

•Magnesium;500mg/day.

•Omega-3 fatty acids: Vascepa, Lovaza or DHA/EPA; 4 g/day.

Omega-3 fatty acids play an important role in the resolution of inflammation by inducing resolvin production.

There is are also numerous recommended medications in the second line and third line therapies. Giving one a multitude of options in treatment.

-DISEASE- SPECIFIC THERAPEUTIC ADJUNCTS

I only covered three diseases here but there a several more. From depression to hair loss. The three I cover I believe may be the most common and most dangerous amongst patients.

-Generalized neurologic symptoms/“brain fog”/fatigue/visual symptoms

•LDN (Low-Dose Naltrexone) appears to play a pivotal role in treatment of many neurological symptoms

•Fluvoxamine. prescription needed.

Some patients report a significant improvement with fluvoxamine while other patients appear to tolerate this drug poorly.

•Nigella Sativa; 200-500 mg twice daily.

•Valproic acid and pentoxifylline may be of value in these patients.

•Non-invasive brain stimulation (NIBS)

These symptoms may be mediated by Mast Cell Activation Syndrome (MCAS)

-Patients with elevated DIC and those with evidence of thrombosis

•These patients should be treated with a NOAC or coumadin for at least three months and then reevaluated for ongoing anticoagulation.

•Patients should continue ASA 81mg/day unless at high risk of bleeding.

•Lumbrokinase activates plasmin and degrades fibrin.

•Turmeric (Curcumin) 500mg twice a day.

Curcumin has anticoagulant, anti platelet and fibrinolytic properties.

-Patients with new onset allergic diathesis/features of Mast Cell Activation Syndrome (MCAS)

•The novel flavanoid luteolin is reported to be a potent mast cell inhibitor.[75,76,78,79]Luteolin 20-100mg/day is suggested.

•Turmeric (curcumin); 500mg/day.

•Curcumin has been reported to block H1 and H2 receptors and to limit mast cell degranulation.

•H1 receptor blockers. Loratadine 10mg/day, Cetirizine 5-10mg/day, Fexofenadine 180mg/day. (Claritin or Zyrtec)

•H2 receptor blockers. Famotidine 20 mg twice daily as tolerated. (Pepcid or Pepcid AC)

•Vitamin C; 1000 mg twice daily.

Vitamin C is strongly recommended for allergic conditions and MCAS. Vitamin C modulates immune cell function and is a potent histamine inhibitor.

•Low histamine diet.

•Montelukast 10 mg/day. Caution as may cause depression is some patients. (Brand name Singulair.)

The efficacy of montelukast as a “mast cell stabilizer’ has been questioned.